On activation by receptors, the ubiquitously expressed class IA isoforms (p110a and p110b) of phosphatidylinositol-3-OH kinase (PI(3)K) generate lipid second messengers, which initiate multiple signal transduction cascades [1] [2] [3] [4] [5] . Recent studies have demonstrated specific functions for p110a in growth factor and insulin signalling [6] [7] [8] . To probe for distinct functions of p110b, we constructed conditional knockout mice. Here we show that ablation of p110b in the livers of the resulting mice leads to impaired insulin sensitivity and glucose homeostasis, while having little effect on phosphorylation of Akt, suggesting the involvement of a kinase-independent role of p110b in insulin metabolic action. Using established mouse embryonic fibroblasts, we found that removal of p110b also had little effect on Akt phosphorylation in response to stimulation by insulin and epidermal growth factor, but resulted in retarded cell proliferation. Reconstitution of p110b-null cells with a wild-type or kinase-dead allele of p110b demonstrated that p110b possesses kinase-independent functions in regulating cell proliferation and trafficking. However, the kinase activity of p110b was required for G-protein-coupled receptor signalling triggered by lysophosphatidic acid and had a function in oncogenic transformation. Most strikingly, in an animal model of prostate tumour formation induced by Pten loss, ablation of p110b (also known as Pik3cb), but not that of p110a (also known as Pik3ca), impeded tumorigenesis with a concomitant diminution of Akt phosphorylation. Taken together, our findings demonstrate both kinase-dependent and kinase-independent functions for p110b, and strongly indicate the kinase-dependent functions of p110b as a promising target in cancer therapy.
On activation by receptors, the ubiquitously expressed class IA isoforms (p110a and p110b) of phosphatidylinositol-3-OH kinase (PI(3)K) generate lipid second messengers, which initiate multiple signal transduction cascades [1] [2] [3] [4] [5] . Recent studies have demonstrated specific functions for p110a in growth factor and insulin signalling [6] [7] [8] . To probe for distinct functions of p110b, we constructed conditional knockout mice. Here we show that ablation of p110b in the livers of the resulting mice leads to impaired insulin sensitivity and glucose homeostasis, while having little effect on phosphorylation of Akt, suggesting the involvement of a kinase-independent role of p110b in insulin metabolic action. Using established mouse embryonic fibroblasts, we found that removal of p110b also had little effect on Akt phosphorylation in response to stimulation by insulin and epidermal growth factor, but resulted in retarded cell proliferation. Reconstitution of p110b-null cells with a wild-type or kinase-dead allele of p110b demonstrated that p110b possesses kinase-independent functions in regulating cell proliferation and trafficking. However, the kinase activity of p110b was required for G-protein-coupled receptor signalling triggered by lysophosphatidic acid and had a function in oncogenic transformation. Most strikingly, in an animal model of prostate tumour formation induced by Pten loss, ablation of p110b (also known as Pik3cb), but not that of p110a (also known as Pik3ca), impeded tumorigenesis with a concomitant diminution of Akt phosphorylation. Taken together, our findings demonstrate both kinase-dependent and kinase-independent functions for p110b, and strongly indicate the kinase-dependent functions of p110b as a promising target in cancer therapy.
Class IA PI(3)Ks are heterodimeric lipid kinases consisting of a p110 catalytic subunit complexed to one of several regulatory subunits, collectively called p85 (refs 4, 5) . In response to stimulation by growth factor, p110 subunits catalyse the production of the lipid second messenger phosphatidylinositol-3,4,5-trisphosphate (PtdIns(3,4,5)P 3 ) at the membrane [1] [2] [3] [4] . This second messenger in turn activates the serine/threonine kinase Akt and other downstream effectors 9, 10 . Knockout mice for either p110a or p110b die early in embryonic development 11, 12 . However, recent studies using conditional knockout strategies 8 and isoform-specific small molecule inhibitors 7 showed that p110a is important in growth-factor signalling, whereas a kinase-inactive knock-in mouse model showed that insulin responses depended on the catalytic activity of p110a (ref. 6) .
To investigate the role(s) of p110b in cell, tissue and organismal physiology and to examine it as a potential therapeutic target in cancer, we generated mice carrying a conditional Pik3cb allele ( Supplementary Fig. 1 ). We first investigated the role of p110b in insulin action. Because liver is the major insulin-responsive organ, we examined the effects of p110b loss on hepatic insulin function. To achieve liver-specific deletion of p110b, we injected the tail veins of p110b flox/flox mice with adenoviruses expressing b-galactosidase (AdeLacZ) or Cre recombinase (Ade-Cre) to generate matched cohorts of control mice and mice with hepatocyte-specific deletion of p110b. Additional cohorts of wild-type animals were subjected to Ade-Cre or Ade-LacZ, allowing us to rule out potential non-specific Cre effects (data not shown). A more than 90% decrease in p110b protein was seen in the livers of Ade-Cre-injected mice, whereas p110b expression remained unchanged in the livers of the control mice and muscle tissues from both groups as measured by western blotting ( Supplementary Fig. 2a, b) . Consistent with previous findings 6, 7 that the kinase activity of p110b has only a minor function in insulin signalling, we saw no significant change in Akt phosphorylation in response to insulin challenge in livers lacking p110b ( Supplementary  Fig. 2a ). However, mice deficient in hepatic p110b had higher levels of insulin in the blood than control animals when fasted (Fig. 1a) . These animals also showed a lower tolerance of glucose and sensitivity to insulin on challenge by intraperitoneal injection of glucose or insulin (Fig. 1b, c) . Mice deficient in hepatic p110b produced more glucose than control animals did in a pyruvate challenge test (Fig. 1d ). An analysis of lipogenesis showed no significant changes in serum triglycerides, fatty acids and cholesterol levels when p110b was deleted from liver ( Supplementary Fig. 3 ), but leptin levels were elevated compared with those in control animals, as was seen in p110a kinase-dead knock-in animals 6 ( Supplementary Fig. 3 ). Of a panel of gluconeogenic genes, only that encoding phosphoenolpyruvate carboxykinase (PEPCK) was increased in p110b-deficient livers ( Supplementary Fig. 4 ). PEPCK promotes the production and synthesis of glucose in liver, resulting in a greater release of glucose into blood. This result therefore provides at least a partial explanation for the metabolic phenotypes observed. Although these findings indicate that p110b might contribute to metabolic regulation through a kinase-independent mechanism, we cannot rule out the involvement of the catalytic role of p110b in insulin responses. Our observations are in line with earlier work 7 in which a p110b-specific small-molecule inhibitor was used to demonstrate that acute blockage of the kinase activity of p110b had little effect on insulin action. In addition, another study 13 found that mice doubly heterozygous for knockout of p110a and p110b showed decreased sensitivity to insulin with no apparent changes in Akt phosphorylation.
To obtain cells for detailed signalling studies, mouse embryonic fibroblasts (MEFs) were isolated from floxed embryos and their wildtype littermates, as described in Supplementary Information ( Supplementary Fig. 5a-c) . MEFs lacking p110b proliferated significantly more slowly than parental (p110b flox/flox ) or wild-type (p110b 1/1 after Cre) MEFs (Fig. 2a) . To obtain a second, more easily renewed supply of knockout cells, we established immortalized p110b flox/flox and p110b 1/1 MEFs by means of infection with a retrovirus encoding a dominant-negative form of p53 (DNp53) 14 . We also generated an add-back line by introducing haemagglutinin (HA)-tagged human p110b to DNp53-immortalized p110b flox/flox MEFs. These immortalized MEFs were then treated with Ade-Cre to yield the following MEF lines: bKO (from p110b flox/flox ) and bKO1b (from the add-back). For wild-type control MEFs, designated WT, we used DNp53-immortalized p110b flox/flox cells without Cre treatment interchangeably with Cre-treated DNp53-immortalized p110b 1/1 MEFs, because no significant differences were ever seen between these two possible controls. Deletion of p110b had no obvious negative effect on the phosphorylation of Akt in either primary MEFs or DNp53-immortalized MEFs in response to stimulation by insulin, epidermal growth factor (EGF) and platelet-derived growth factor ( Fig. 2c and Supplementary Fig. 6a-c) . However, a moderate diminution in the phosphorylation of the S6 ribosomal protein (S6RP) at Ser 235/Ser 236 was detected in these bKO cells in response to insulin or serum ( Supplementary Fig. 7 ). Previous studies have implicated p110b in signalling elicited by G-protein-coupled receptors (GPCRs) 15, 16 . We found consistently that both phospho-Akt and phospho-S6RP levels were decreased in response to lysophosphatidic acid (LPA) in cells lacking p110b ( Fig. 2d and Supplementary Fig.  8a ).
To dissect the potential kinase-dependent and kinase-independent roles of p110b, we reconstituted bKO MEFs with a kinase-inactive allele of HA-tagged human p110b, using the previously reported K805R mutation (KR) 17 to generate the bKO1KR MEF line. Though the expression of KR was lower than that of the WT addback construct, it was expressed at a level slightly higher than endogenous p110b, and expression levels of p110a were unchanged ( Supplementary Fig. 9a , and data not shown). Loss of lipid kinase activity in the KR cells was confirmed by lipid kinase assay 8, 18 after immunoprecipitation with anti-p110b ( Supplementary Fig. 9b ). We then examined the effect of WT or KR add-back on the altered signalling seen after the loss of p110b. The decrease in both phosphoAkt and phospho-S6RP in response to stimulation with LPA observed in bKO cells was restored by adding back WT but not the KR allele of p110b ( Fig. 2d and Supplementary Fig. 8b ), suggesting a catalytic function for p110b in LPA signalling. This seems to be unique to p110b, because loss of p110a has no obvious effect on LPA signalling (Fig. 2e) . The lower phospho-S6RP levels in bKO cells were restored by both WT and KR add-backs in response to insulin or fetal bovine serum (FBS) (Supplementary Fig. 7 , and data not shown), suggesting a scaffolding role of p110b in signalling by insulin and growth factors. However, our MEF data do not rule out a role for p110b in classical signalling by PI(3)K in other circumstances. For instance, when we ablated p110a in our earlier work, residual phosphorylation by Akt was observed in response to growth factors 8 . Because MEFs express p110a and p110b and not other class I PI(3)Ks, this residual signal was presumably transduced by p110b. We also note that p110b ablation removes the protein as a competitor for p110a on receptors, which may allow any decrease in signalling caused by p110b loss to be masked or compensated for by an increased signal flux through p110a.
To test the kinase-dependent and/or kinase-independent effects of p110b on cell proliferation, we studied cell cycle kinetics by first synchronizing cells by serum starvation and then measuring the proportion of cells in S phase with the incorporation of bromodeoxyuridine (BrdU) after re-feeding. Whereas bKO cells had a delayed peak of BrdU incorporation, KR reconstituted cells showed a similar incorporation of BrdU to that of WT and bKO1b cells (Fig. 2f) . Consistently, bKO1KR MEFs showed proliferation rates similar to those of WT and bKO1b cells (Supplementary Fig. 9c ), suggesting a kinase-independent role of p110b in cell proliferation. Because previous studies have found p110b associated with members of the Rab family of small G proteins and clathrin-coated vesicles 19 , we measured transferrin uptake in bKO MEFs and found it to be defective compared with that in WT and bKO1b MEFs (Fig. 2g) . Interestingly, normal uptake of transferrin was restored by the KR construct (Fig. 2g) . Although there is ample published evidence indicating the importance of transferrin uptake for the growth of a variety of cell types 20 , it is not clear whether the defect in transferrin uptake is a primary cause of the growth defect observed here.
Class IA PI(3)Ks have been clearly implicated in cancer [21] [22] [23] [24] , with much recent work delineating the role of p110a in cancer [25] [26] [27] . To study a potential role of p110b in oncogenic transformation, we performed focus formation assays by infecting monolayers of DNp53-immortalized MEFs with retroviruses expressing various oncogenes. Oncogenic HRas-G12V and EGFR-Del (DL747-E749, A750P) retroviruses efficiently raised foci in WT cells but failed to transform bKO MEFs (Fig. 3a) . The decreases in foci seen in bKO MEFs were actually more pronounced than those seen in p110a KO MEFs ( Supplementary Fig. 10 ). Transformation was fully restored in bKO1b cells but partly restored in bKO1KR cells (Fig. 3a) , suggesting that both the kinase activity and kinase-independent functions of p110b may have a function in oncogene-induced transformation.
PTEN, a lipid phosphatase, functions to oppose class IA PI(3)K kinase activity. Loss of Pten expression is a common event in many solid tumours 28 . The key challenge is to identify which p110 isoform's catalytic activity is unshackled by Pten loss in any given tumour. To test for a role of p110b in tumorigenesis driven by Pten loss, we generated mice that carried the Pten flox/flox (ref. 29 ) and p110b flox/flox alleles, as well as a probasin-driven Cre transgene 30 , to specifically delete Pten and p110b in prostatic epithelium. Prostates had a normal appearance in the absence of p110b (Fig. 3b, c) . Prostate tissue lacking Pten expression showed universal high-grade prostatic intraepithelial neoplasia in the anterior lobe by 12 weeks. Ablation of p110b blocked the tumorigenesis caused by Pten loss in the anterior prostate (Table 1 and Fig. 3b, c) . The loss of Pten was confirmed by genomic DNA analysis after laser-capture-assisted microdissection of single epithelial layers and by western blotting (Supplementary Fig.  11 , and data not shown). Whereas Cre-mediated loss of Pten efficiently activated Akt in the prostate as judged by its phosphorylation on Ser 473, additional ablation of p110b diminished the phosphoAkt levels (Fig. 3b) , suggesting that p110b catalytic activity contributes to tumorigenesis. More surprisingly, when we performed the same set of experiments using p110a ablation, we saw no changes either in tumour formation or in Akt phosphorylation (Table 1 and Fig. 3b, c) . Again, the complete excision of p110a in tumour tissues was confirmed by multiple measures (Supplementary Fig. 12 , and data not shown). It has been suggested that p110a and p110b generate distinct pools of PtdIns(3,4,5)P 3 (ref. 7) . In response to insulin or other stimuli, an acute flux of PtdIns(3,4,5)P 3 is produced largely by p110a and is efficiently coupled to Akt phosphorylation. In contrast, p110b has been proposed to generate a basal level of PtdIns(3,4,5)P 3 with little effect on Akt phosphorylation 7 . It was shown that Akt phophorylation induced by Pten loss in vitro was sensitive to p110b-specific inhibitors 7 . We propose that it is this basal PtdIns(3,4,5)P 3 signal that has been enhanced to drive transformation and Akt activation by Pten loss in the murine prostate (Fig. 3d) . Alternatively, the differential effects of p110a and p110b ablation may arise because the signal activating PI(3)K is generated by an as yet unidentified GPCR or a receptor tyrosine kinase that functions through p110b.
Thus, our data suggest distinct functions for p110b and p110a in cell signalling and transformation. We have showed that p110b has an important physiological function in metabolic regulation and glucose homeostasis, perhaps involving a kinase-independent mechanism. A kinase-independent function of p110b was further suggested in controlling cell proliferation and trafficking in p110b KO MEFs and MEFs reconstituted with a WT or kinase-dead allele of p110b. It would clearly be a mistake to overlook the contributions of p110b as a kinase. The basal PtdIns(3,4,5)P 3 pool catalysed by p110b seems to be 'silent' in response to stimulation by insulin and other growth factors, but becomes a 'powerhouse' to drive oncogenic 
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Paraffin sections of anterior prostates from the indicated strains at 12 weeks were stained with haematoxylin/eosin. The pathological phenotype was uniformly observed within each genotype and is summarized in the table. PIN, prostatic intraepithelial neoplasia.
transformation in the absence of PTEN, as evident in our mouse prostate tumour model. Taken together, our findings indicate that p110b may be an attractive target for kinase inhibitors in cancer treatment with minor metabolic disturbances.
METHODS SUMMARY
Mice carrying floxed p110b (generated in this work), floxed p110a (ref. 8) , floxed Pten 29 and probasin-driven Cre transgene 30 (Mouse Models of Human Cancers Consortium (MMHCC), National Cancer Institute) were used in this study. All animals were housed and treated in accordance with protocols approved by the Institutional Animal Care and Use Committees of Dana-Farber Cancer Institute and Harvard Medical School. The generation, culture and immortalization of MEFs, growth factor signalling study, retroviral infection, cell growth, cell cycle, lipid kinase assay, transferrin internalization, focus formation, glucose tolerance testing, insulin tolerance tests, pyruvate challenge, immunoprecipitation, immunoblotting, immunohistochemical and histological analyses were performed in accordance with standard or published protocols. Statistical analyses were performed with Student's t-test unless otherwise indicated.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
METHODS
Mice for metabolic and tumour studies. Conditional knockout mice of p110b were generated using the Cre-LoxP system. In brief, the targeting construct was assembled by isolating a 7.5-kilobase genomic fragment of Pik3cb from 129SvEv mouse strain and inserting two LoxP sites to flank exon 2 of Pik3cb. The targeting construct was electroporated into embryonic stem (ES) cells of 129SvEv mouse. ES clones carrying floxed Pik3cb were injected into the blastocysts of C57BL/6 mice. Male chimaeras were bred to C57BL/6 females to establish germline transmission of the conditional allele. The resulting heterozygous line (p110b flox/1 ) was intercrossed to yield a homozygous line (p110b flox/flox ). For metabolic studies, 8-10-week-old male p110b flox/flox littermates were tailvein injected with 75 ml of adenovirus CMV-lacZ and CMV-cre (titre between 10 10 and 4 3 10 10 plaque-forming units ml 21 ; University of Iowa Gene Transfer Vector Core). Two weeks after injection of adenoviruses, glucose tolerance test, insulin tolerance test, pyruvate challenge and in vivo insulin signalling were performed as described previously 31 . Blood glucose values were determined with an Accu-Chek AVIVA glucose monitor (Roche) . Serum insulin and leptin (Crystal Chem Inc.), serum-free fatty acids and triacylglycerols (Wako) and serum cholesterol (Thermo) were measured by ELISA in accordance with the manufacturer's instructions.
It took two steps to generate compound mice for tumour studies. All floxed mice used were originally in the 129-C57BL/6 background and had been backcrossed once to C57BL/6. The probasin Cre mice were in the C57BL/6 background. In step 1, male PbCre4 mice were first crossed to the female Pten ), and no significant differences were observed between these groups.
In flox/flox to generate larger numbers of the desired compound strains. No differences were seen in phenotypes in compound animals generated by either version of step 2. Primary and immortalized MEFs. MEFs were prepared from embryos derived from intercrossing p110b flox/1 heterozygotes at embryonic day 13.5 after fertilization. Primary WT or floxed MEFs, and DNp53 immortalized WT or floxed MEFs were treated with Ade-Cre to generate WT control and p110b-null (bKO) cells. Additional control cells used in our study were floxed MEFs without AdeCre treatment. bKO1b and bKO1KR lines were generated by introducing either HA-tagged WT human p110b or a kinase-inactive mutant K805R into bKO MEFs and then treated with Ade-Cre. Genotyping of MEFs was done by PCR using primer sets: LLF with LLR, and SLF with LLR ( Supplementary Fig. 1 ). Growth factors and western blotting. Cells were starved either for 2 h or overnight followed by stimulation with insulin (2.5 mg ml 
